Virtus Biotech ETF
BBP
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Virtus LifeSci Biotech Products ETF (BBP) is an exchange-traded fund that seeks investment results corresponding, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The fund provides passive, equally weighted exposure to U.S. exchange-listed biotechnology companies that have at least one FDA-approved drug therapy available for sale and marketing; it invests not less than 80% of its net assets in the index's component securities, focusing on firms across small-, mid-, and large-cap market capitalizations in the biotechnology and life sciences sectors. Top holdings as of late 2025 include Incyte Corp, Kura Oncology Inc, Amicus Therapeutics Inc, Syndax Pharmaceuticals Inc, and Amgen Inc, with portfolio turnover at 46% for the fiscal year ended October 31, 2024. Launched on December 16, 2014, and domiciled in the United States, the ETF is managed by Virtus ETF Advisers LLC, a subsidiary of Virtus Investment Partners, Inc., with index provision by LifeSci Index Partners, LLC. Virtus Investment Partners maintains corporate headquarters in Hartford, Connecticut, while LifeSci Index Partners is based in New York, New York. The fund targets investors seeking high-growth potential in the dynamic biotechnology sector, with geographic exposure primarily to U.S. companies (approximately 95%), alongside minor allocations to developed markets including China, the United Kingdom, Denmark, and Canada. The ETF carries a total expense ratio of 0.79% and distributes dividends annually on a 1099 tax basis, with assets under management reaching approximately $31 million as of December 2025. It trades on NYSE Arca and emphasizes pure exposure to biotech firms that have successfully completed human clinical trials and obtained FDA approvals, distinguishing it from broader or clinical-stage biotech funds. As part of ETFis Series Trust I, the fund employs a full replication strategy without derivatives or currency hedging. In recent developments, Virtus Investment Partners completed the acquisition of a 35% minority interest in Crescent Cove Advisors, LP on December 16, 2025, expanding its platform with private markets lending to high-growth technology companies, though this does not directly impact BBP operations. The ETF itself reflects ongoing semi-annual index rebalances to maintain equal weightings, supporting performance from small firms with breakthroughs, amid a fiscal 2024 portfolio turnover of 46%. No BBP-specific acquisitions, funding rounds, or product launches were reported in 2024-2025, with focus remaining on tracking the LifeSci Biotechnology Products Index.